Update on the efficacy and safety of Nex-Z in ATTR-CM from the phase 1 program #AHA2025 #Cardiobluesky
The phase III is on hold pending evaluation of liver-related safety events
#MedIQAHA25
1
0
1
0
Hashtag
#MedIQAHA25
Advertisement · 728 × 90
Finally it is here
The phase 2 Coramitug (PRX004)
Lots to think about
Placebo controlled, 2 levels 10 and 60 mg/kg
#AHA2025
#cardiobluesky
#MedIQAHA25
Paper out in t.co/cuSyqw4KBk
0
0
1
0
Another look at serum TTR in ATTRibute-CM trial. Significant difference in outcomes based on dichotomizing sTTR to > vs <20
#CardioBluesky
#AHA2025
#MedIQAHA25
0
0
1
0
A post hoc analysis from ATTRibute-CM where acoramidis improved clinical outcomes regardless of AF status
#cardiobluesky
#AHA2025
#MedIQAHA25
1
0
1
0
LA strain but not volume was associated with outcomes in #HELIOS-B (vutrisiran vs placebo).
Vutrisiran attenuates worsening of LA strain #AHA2025
#cardiobluesky
#MedIQAHA25
0
0
1
0
Effect of acoramidis vs placebo on V122I from ATTRibute-CM presented #AHA2025 and published in
@jamacardiology.com
#cardiobluesky
#MedIQAHA25
1
0
1
0
Variant data from subgroup analysis in #ATTR-CM from the ATTRibute-CM trial and its OLE (acoramidis vs placebo)
#Cardiobluesky
#AHA2025
#MedIQAHA25
1
0
1
0
0
0
1
0
0
0
1
0
1
0
2
0
0
0
1
0
Proteomics in ATTR amyloidosis Authors dive into unregulated pathways and outcomes #AHA2025 #MedIQAHA25
1
0
2
0
#AHA2025
In cardiac #amyloidosis, this EKG algorithm had 97% sens and 40% spec for the diagnosis. This impacts accuracy.
#CardioBluesky
#MedIQAHA25
1
0
1
0
Thank you to Dr. Ahmad Masri for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #AHA25. Check out this thread for highlights.
#CardioBluesky #MedIQAHA25
0
0
1
0